Incorporating a personalized mRNA vaccine, designed to match an individual’s tumor genetics, into standard immunotherapy substantially boosts survival rates and reduces the recurrence of high-risk skin cancers in patients who have had these malignancies removed.
Global trials that could revolutionize cancer treatment and save countless lives are being led by scientists from Edith Cowan University (ECU).
Clinical Professor Adnan Khattak from ECU’s Centre for Precision Health recently unveiled the newest findings from these trials at the 2023 American Society of Oncology (ASCO) congress in Chicago. The ASCO congress, attracting more than 45,000 participants, is the largest cancer treatment conference worldwide.
After 18 months, cancer-free survival among patients who received the vaccine and the immunotherapy treatment was 78.6 percent, compared to 62.2 percent of those who only received the immunotherapy.
Two years after treatment, only 22.4 percent of patients who had received the vaccine/immunotherapy combination had either died or seen a recurrence of the disease, which rose to 40 percent for the immunotherapy-only group.
Overall, after an average of two years, those who received the vaccine saw a 44 percent lower risk of death or melanoma returning to the same area of the body, and a 65 percent reduction in the risk of death or the cancer returning in a different area of the body.
Crucially, there was no significant increase in rates of adverse side effects.
Professor Khattak said the trial began as a way of trying to address the shortcomings of current treatments.
“The current standard of care is immunotherapy using an antibody known as pembrolizumab,” he said.
“There are two main issues: first, despite having active immunotherapy for stage three melanoma, about half of the patients will relapse at five years.
“And secondly, it’s a very crude approach: currently if I treat 10 new high-risk melanoma patients, I give them the same drug; it’s not rocket science that it’s going to work for some but not others, and some may see side effects and others may not.
“This is the biggest trial to show treatment improves with an individualized approach — and I think research into personal cancer vaccines is going to increase dramatically after this positive study.”
Getting to know you — and your disease
Though vaccines are typically associated with disease prevention, in this instance the mRNA vaccine is used to treat people who have already been diagnosed with melanoma.
Samples of tissue are taken and analyzed to identify neoantigens, proteins that form on cancer cells, and which are unique to an individual’s tumor.
Up to 34 neoantigens may be identified, which are then added to an mRNA molecule and added to a vaccine.
The result is a personalized cancer treatment, with the neoantigens most likely to develop an immune response to help the patient’s body fight cancer.
Professor Khattak said it appeared to be more effective after an extended period of time and required multiple doses.
“In this study, the survival rate between the two groups is the same after 40 weeks, so early relapses happen for both,” he said.
“Some patients have fairly resistant tumors that aren’t going to respond to either of the treatments.
“But after the first 40 weeks, by then the patients have had two or three vaccine doses and the anti-tumor effect really kicks in.
“We see quite a significant proportion of patients relapsing after they finish pembrolizumab, whereas we’re not seeing such late relapses in patients who have done the double treatment because in addition to pembrolizumab, the effect of the vaccine kicks in with a much stronger anti-tumor immune response.”
Next steps
Professor Khattak will soon lead a new global trial of the treatment,
His clinic in Perth, Western Australia recruited the most participants of any site in the world.
“I would like to thank all my patients who took part in this research at a difficult point in their life,” Professor Khattak said.
The new trial will include more participants, some with earlier stages of melanoma.
“Stage two and stage three patients combined constitute quite a significant proportion of patients who could be potentially cured, rather than waiting for them to develop metastatic or advanced disease where most of them will not be curable,” he said.
If successful, the trial could be the starting point of a new approach to cancer treatment, beyond just melanoma.
“This is going to be the stepping stone for a number of trials,” Professor Khattak said.
“Because now they have expanded it into lung cancer, kidney cancers, and also into gastrointestinal cancers.
“This has the potential of becoming a new standard of care moving forward.”
Meeting: 2023 American Society of Oncology
Those looking for details on the trial can contact One Clinical Research.
The research was funded by Moderna, Merck Sharp and Dohme.
![](https://www.nanoappsmedical.com/wp-content/uploads/2017/05/spacer.jpg)
News
Breakthrough in Antimicrobial Technology with Cinnamon-Based Nanokiller
The need for innovative antimicrobial agents has become increasingly urgent due to the rise of antibiotic-resistant pathogens and the persistent threat of infections acquired during hospital stays. Traditional antibiotics and antiseptics are often ineffective [...]
The Silent Battle Within: How Your Organs Choose Between Mom and Dad’s Genes
Research reveals that selective expression of maternal or paternal X chromosomes varies by organ, driven by cellular competition. A new study published today (July 26) in Nature Genetics by the Lymphoid Development Group at the MRC [...]
Study identifies genes increasing risk of severe COVID-19
Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in [...]
Small regions of the brain can take micro-naps while the rest of the brain is awake and vice versa
Sleep and wake: They're totally distinct states of being that define the boundaries of our daily lives. For years, scientists have measured the difference between these instinctual brain processes by observing brain waves, with [...]
Redefining Consciousness: Small Regions of the Brain Can Take Micro-Naps While the Rest of the Brain Is Awake
The study broadly reveals how fast brain waves, previously overlooked, establish fundamental patterns of sleep and wakefulness. Scientists have developed a new method to analyze sleep and wake states by detecting ultra-fast neuronal activity [...]
AI Reveals Health Secrets Through Facial Temperature Mapping
Researchers have found that different facial temperatures correlate with chronic illnesses like diabetes and high blood pressure, and these can be detected using AI with thermal cameras. They highlight the potential of this technology [...]
Breakthrough in aging research: Blocking IL-11 extends lifespan and improves health in mice
In a recent study published in the journal Nature, a team of researchers used murine models and various pharmacological and genetic approaches to examine whether pro-inflammatory signaling involving interleukin (IL)-11, which activates signaling molecules such [...]
Promise for a universal influenza vaccine: Scientists validate theory using 1918 flu virus
New research led by Oregon Health & Science University reveals a promising approach to developing a universal influenza vaccine—a so-called "one and done" vaccine that confers lifetime immunity against an evolving virus. The study, [...]
New Projects Aim To Pioneer the Future of Neuroscience
One study will investigate the alterations in brain activity at the cellular level caused by psilocybin, the psychoactive substance found in “magic mushrooms.” How do neurons respond to the effects of magic mushrooms? What [...]
Decoding the Decline: Scientific Insights Into Long COVID’s Retreat
Research indicates a significant reduction in long COVID risk, largely due to vaccination and the virus’s evolution. The study analyzes data from over 441,000 veterans, showing lower rates of long COVID among vaccinated individuals compared [...]
Silicon Transformed: A Breakthrough in Laser Nanofabrication
A new method enables precise nanofabrication inside silicon using spatial light modulation and laser pulses, creating advanced nanostructures for potential use in electronics and photonics. Silicon, the cornerstone of modern electronics, photovoltaics, and photonics, [...]
Caught in the actinium: New research could help design better cancer treatments
The element actinium was first discovered at the turn of the 20th century, but even now, nearly 125 years later, researchers still don't have a good grasp on the metal's chemistry. That's because actinium [...]
Innovative Light-Controlled Drugs Could Revolutionize Neuropathic Pain Treatment
A team of researchers from the Institute for Bioengineering of Catalonia (IBEC) has developed light-activated derivatives of the anti-epileptic drug carbamazepine to treat neuropathic pain. Light can be harnessed to target drugs to specific [...]
Green Gold: Turning E-Waste Into a Treasure Trove of Rare Earth Metals
Scientists are developing a process inspired by nature that efficiently recovers europium from old fluorescent lamps. The approach could lead to the long-awaited recycling of rare earth metals. A small molecule that naturally serves [...]
Cambridge Study: AI Chatbots Have an “Empathy Gap,” and It Could Be Dangerous
A new study suggests a framework for “Child Safe AI” in response to recent incidents showing that many children perceive chatbots as quasi-human and reliable. A study has indicated that AI chatbots often exhibit [...]
Nanoparticle-based delivery system could offer treatment for diabetics with rare insulin allergy
Up to 3% of people with diabetes have an allergic reaction to insulin. A team at Forschungszentrum Jülich has now studied a method that could be used to deliver the active substance into the [...]